State Drug Alert: 147 Medicine Samples Fail CDSCO Quality Tests in January 2026

Written By :  Susmita Roy
Published On 2026-02-25 08:08 GMT   |   Update On 2026-02-25 08:08 GMT

New Delhi: Highlighting continuing concerns over medicine quality, the Central Drugs Standard Control Organisation (CDSCO) has released its January 2026 drug alert, listing 147 formulations that failed to comply with pharmacopoeial specifications based on analyses conducted by State Drug Testing Laboratories (SDTLs) across India.

The findings are derived from regulatory surveillance samples collected by state drug inspectors and tested at government laboratories. The alert covers a broad spectrum of dosage forms including tablets, capsules, injections, syrups, creams, and suspensions, spanning therapeutic categories such as cardiovascular medicines, antibiotics, gastrointestinal drugs, respiratory syrups, dermatological preparations, and analgesics.

Among the products reported were commonly prescribed combinations like Telmisartan & Amlodipine Tablets IP manufactured by Zoic Biotech, Multivitamin Tablets N.F.I. manufactured by Healthy Life Pharma, Levosalbutamol Sulphate, Ambroxol Hydrochloride & Guaiphenesin Syrup manufactured by Innova Captab, Diclofenac Sodium Injection manufactured by Neon Laboratories,Amoxycillin & Potassium Clavulanate Tablets IP manufactured by Mayer Lab, Flunarizine Tablets IP 10mg manufactured by Pure & Cure Healthcare, Albendazole Tablets IP 400 mg manufactured by Hindustan Antibiotics and etc.

The list further inclued Crypsin-Chyostypsin Tablets manufactured by Torrent Pharmaceuticals , and Terbutaline Sulphate, Bromhexine Hcl, Guaiphenesin Syrup manufactured by Dr.Reddy's Laboratories.

According to laboratory reports, the observed failures included dissolution test failures, assay non-compliance, description defects, sterility failures, and content irregularities. Such deviations may impact therapeutic efficacy, stability, or patient safety depending on the nature of the defect.

Also Read: CDSCO Finds 93 Medicines Samples Substandard, Key Antibiotics, Chronic Drugs Affected

Under the Drugs and Cosmetics Act, 1940, a drug is deemed “Not of Standard Quality” if it fails to meet the standards specified in the Second Schedule of the Act. Section 16(1)(a) defines the ‘standards of quality’ as compliance with those prescribed requirements

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News